Online inquiry

IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7403MR)

This product GTTS-WQ7403MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7403MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10319MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ2992MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ14090MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ9706MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ11358MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ1792MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ5755MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ4671MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986089
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW